Zura Bio (NASDAQ: ZURA) raises cash to fund Phase 2 trials
Rhea-AI Filing Summary
Zura Bio Limited reported full-year 2025 results and highlighted progress across its clinical pipeline and financing. The company posted a net loss of
Cash and cash equivalents were
The Phase 2 TibuSHIELD study in hidradenitis suppurativa expanded planned enrollment to 225 participants, with topline data expected in the fourth quarter of
Positive
- None.
Negative
- None.
Insights
Higher R&D spending drives losses, but cash runway extends to 2028.
Zura Bio is clearly prioritizing pipeline advancement. Research and development costs rose to
Despite a 2025 net loss of
Key upcoming catalysts are topline Phase 2 data from the TibuSHIELD study in the fourth quarter of
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
Current Report
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(I.R.S. Employer Identification No.) |
(Address of principal
executive offices,
including zip code)
(
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name
of each exchange on which registered | ||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant
to Section 13(a) of the Exchange Act.
| Item 2.02. | Results of Operations and Financial Condition. |
On March 19, 2026, Zura Bio Limited (the “Company”) issued a press release announcing its 2025 full fiscal year financial results. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.
The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed incorporated by reference into any other filing with Securities and Exchange Commission (the “SEC”) made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.
| Item 7.01. | Regulation FD Disclosure. |
On March 19, 2026, the Company provided an updated corporate presentation that may be used in connection with upcoming presentations at conferences and investor meetings. The full text of the Company’s corporate presentation is filed as Exhibit 99.2 hereto, and incorporated herein by reference, and may also be accessed through the “News & Events” section of the Company’s website at investors.zurabio.com.
The information furnished under this Item 7.01 (including Exhibit 99.2), shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act. The information in this Item 7.01 (including Exhibit 99.2) shall not be deemed incorporated by reference into any other filing with the SEC made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Press Release dated March 19, 2026 | |
| 99.2 | Corporate Presentation, dated March 19, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| ZURA BIO LIMITED | ||
| Date: March 19, 2026 | By: | /s/ Kim Davis |
| Kim Davis | ||
| Chief Operating Officer, Chief Legal Officer and Corporate Secretary | ||
Exhibit 99.1
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates
| · | Advancing two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) and systemic sclerosis (SSc) |
| · | Topline data expected from the Phase 2 TibuSHIELD study in HS in the fourth quarter of 2026 and from the Phase 2 TibuSURE study in SSc in the first half of 2027 |
| · | Cash and cash equivalents of $109.4 million as of December 31, 2025 |
| · | Completed an underwritten public offering in February 2026 for gross proceeds of approximately $144 million; post-financing cash and cash equivalents expected to support planned operations through at least the end of 2028 |
HENDERSON, Nev.--(BUSINESS WIRE)--March 19, 2026-- Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported financial results for the full year ended December 31, 2025, and provided recent corporate updates.
“2025 was a year of strong execution for Zura, marked by meaningful progress across our Phase 2 programs and a disciplined focus on advancing our clinical strategy,” said Sandeep Kulkarni, M.D., co-founder and Chief Executive Officer of Zura Bio. “We enter 2026 with momentum, supported by a strengthened balance sheet and a focused plan to advance tibulizumab, our lead program and a potential first- and only-in-class bispecific antibody targeting the interleukin-17 and B-cell activating factor pathways. With multiple anticipated Phase 2 data readouts ahead, including topline data from our TibuSHIELD study expected in the fourth quarter of 2026, we believe Zura is well positioned as we move into an important phase of clinical execution and value creation.”
CORPORATE HIGHLIGHTS AND ANTICIPATED MILESTONES
Tibulizumab (ZB-106)
Hidradenitis suppurativa (HS) – Phase 2 TibuSHIELD
The Phase 2 TibuSHIELD clinical study evaluating tibulizumab in adult participants with HS is ongoing. To enhance statistical power, Zura expanded planned enrollment to 225 participants. Topline data are anticipated in the fourth quarter of 2026.
Systemic sclerosis (SSc) – Phase 2 TibuSURE
The Phase 2 TibuSURE clinical study evaluating tibulizumab in adult participants with SSc is ongoing, with topline data anticipated in the first half of 2027.
Additional Clinical Stage Product Candidates
In addition to tibulizumab, Zura is continuing to evaluate potential future development strategies for crebankitug (ZB-168) and torudokimab (ZB-880), informed by available clinical and translational data and by the evolving competitive landscape.
2026 UPDATES SUBSEQUENT TO YEAR END
Leadership Updates
In January 2026, Zura appointed Sandeep Kulkarni, M.D., as Chief Executive Officer. In February 2026, Zura appointed Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors.
Balance Sheet Strengthening
In February 2026, Zura closed an underwritten public offering of Class A ordinary shares and pre-funded warrants to purchase Class A ordinary shares, resulting in gross proceeds of approximately $144 million, before deducting underwriting discounts, commissions, and offering expenses.
FINANCIAL RESULTS FOR FULL YEAR 2025
Cash Position
Cash and cash equivalents were $109.4 million as of December 31, 2025, compared to $176.5 million as of December 31, 2024.
Cash Runway (Pro-Forma Post-Financing)
Based on its current operating plans, and after giving effect to the completion of the February 2026 public offering, Zura believes that its existing cash and cash equivalents are sufficient to support planned operations through at least the end of 2028.
Research and Development (R&D) Expenses
R&D expenses were $42.1 million for the year ended December 31, 2025, compared to $24.4 million for the year ended December 31, 2024. The increase was primarily driven by continued advancement of Zura’s Phase 2 tibulizumab clinical programs, including increased payments to contract research organizations and contract development and manufacturing organizations. The increase was partially offset by the reversal of a $5.0 million accrued obligation following the December 29, 2025 BAFFX17 Settlement and Release Agreement.
General and Administrative (G&A) Expenses
G&A expenses were $33.2 million for the year ended December 31, 2025, compared to $30.8 million for the year ended December 31, 2024. The increase was primarily due to higher costs to support the Company’s continued growth and advancement of its Phase 2 tibulizumab clinical programs.
Net Loss
Net loss was $68.7 million for the year ended December 31, 2025, compared to $52.4 million for the year ended December 31, 2024.
Net Loss Attributable to Class A Ordinary Shareholders
Net loss attributable to Class A ordinary shareholders was $99.4 million, or $(1.06) per basic and diluted share, compared to $45.4 million, or $(0.60) per share, for the year ended December 31, 2024.
ZURA BIO LIMITED
CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
| December 31, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 109,407 | $ | 176,498 | ||||
| Prepaid expenses and other current assets | 2,903 | 2,246 | ||||||
| Total current assets | 112,310 | 178,744 | ||||||
| Property and equipment, net | 126 | 91 | ||||||
| Other assets | 1,512 | 698 | ||||||
| Total assets | $ | 113,948 | $ | 179,533 | ||||
| Liabilities, Redeemable Noncontrolling Interest and Shareholders’ Equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued expenses | $ | 12,410 | $ | 19,514 | ||||
| Total current liabilities | 12,410 | 19,514 | ||||||
| Total liabilities | 12,410 | 19,514 | ||||||
| Redeemable noncontrolling interest | — | 11,663 | ||||||
| Shareholders’ Equity | ||||||||
| Class A Ordinary Shares, $0.0001 par value; 300,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 73,680,710 and 65,297,530 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | 7 | 7 | ||||||
| Additional paid-in capital | 326,078 | 302,705 | ||||||
| Accumulated deficit | (224,547 | ) | (155,897 | ) | ||||
| Total Zura Bio Limited shareholders’ equity | 101,538 | 146,815 | ||||||
| Noncontrolling interest | — | 1,541 | ||||||
| Total shareholders’ equity | 101,538 | 148,356 | ||||||
| Total liabilities, redeemable noncontrolling interest and shareholders’ equity | $ | 113,948 | $ | 179,533 | ||||
ZURA BIO LIMITED
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share data)
For the Years Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| Operating expenses: | ||||||||
| Research and development | $ | 42,082 | $ | 24,401 | ||||
| General and administrative | 33,164 | 30,788 | ||||||
| Total operating expenses | 75,246 | 55,189 | ||||||
| Loss from operations | (75,246 | ) | (55,189 | ) | ||||
| Other (income)/expense, net: | ||||||||
| Interest income | (6,336 | ) | (7,998 | ) | ||||
| Change in fair value of private placement warrants | — | 5,240 | ||||||
| Other income, net | (260 | ) | (28 | ) | ||||
| Total other (income)/expense, net | (6,596 | ) | (2,786 | ) | ||||
| Loss before income taxes | (68,650 | ) | (52,403 | ) | ||||
| Income tax benefit | — | — | ||||||
| Net loss | (68,650 | ) | (52,403 | ) | ||||
| Adjustment of redeemable noncontrolling interest | 831 | 7,017 | ||||||
| Accretion of redeemable noncontrolling interest to redemption value | 4,868 | — | ||||||
| Deemed dividend on extinguishment of noncontrolling interest and redeemable noncontrolling interest | (36,402 | ) | — | |||||
| Net loss attributable to Class A Ordinary Shareholders of Zura | $ | (99,353 | ) | $ | (45,386 | ) | ||
| Net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted | $ | (1.06 | ) | $ | (0.60 | ) | ||
| Weighted-average Class A Ordinary Shares used in computing net loss per share attributable to Class A Ordinary Shareholders of Zura, basic and diluted | 94,160,138 | 75,070,761 | ||||||
ABOUT ZURA
Zura is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet need. Zura’s pipeline includes product candidates designed to target key mechanisms of immune system imbalance, with the goal of improving efficacy, safety, and dosing convenience for patients.
Zura’s lead product candidate, tibulizumab (ZB-106), is being evaluated in two Phase 2 clinical studies in adults: TibuSHIELD, a study in hidradenitis suppurativa (HS), and TibuSURE, a study in systemic sclerosis (SSc). Additional product candidates crebankitug (ZB-168) and torudokimab (ZB-880) have completed Phase 1/1b studies and are being evaluated for their potential across a range of autoimmune and inflammatory conditions.
For more information, please visit www.zurabio.com.
FORWARD-LOOKING STATEMENTS
Any statements contained in this press release that do not describe historical facts may constitute “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “anticipate,” “believe,” “continue,” “could,” “designed to,” “expect,” “goal,” “intend,” “may,” “outlook,” “plan,” “potential,” “should,” “will,” and similar expressions, and are based on Zura’s current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding the development and potential therapeutic benefits of Zura’s product candidates; the timing, progress, design and results of Zura’s current and future clinical trials, including the reporting of data therefrom; the timing and potential to expand Zura’s product candidates into additional indications; the sufficiency of Zura’s cash resources and projected cash runway; and other statements that are not historical facts. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such forward-looking statements. Risks and uncertainties that may cause actual results to differ materially include, but are not limited to: uncertainties inherent in the development of therapeutic product candidates, such as the risk that one or more of Zura’s current or future product candidates may not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Zura’s current or future product candidates; the risk that prior results, including signals of safety, activity or durability of effect observed in preclinical studies or earlier clinical trials, may not be replicated or may not continue in ongoing or future studies or clinical trials; the risk that modeling data indicating therapeutic potential, or clinical evidence from other drug candidates, may not be predictive of results in Zura’s current or future clinical trials; the risk that Zura’s product candidates or procedures in connection with their administration may not have the safety or efficacy profiles anticipated; risks related to the accuracy of Zura’s estimates of expenses, capital requirements and needs for additional financing; changes in expected or existing competition; changes in the regulatory environment; uncertainties related to the timing and outcome of the regulatory approval process; unexpected litigation or other disputes; the impact of macroeconomic conditions on Zura’s business, clinical trials and financial position; and other risks and uncertainties to be described in Zura’s Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the Securities and Exchange Commission. Any forward-looking statements speak only as of the date of this press release and are based on information available to Zura as of the date hereof. Zura assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
CONTACTS
Megan K. Weinshank
Head of Corporate Affairs
ir@zurabio.com
Exhibit 99.2
| Corporate overview March 2026 Nasdaq Ticker: ZURA |
| ©2026 Zura Bio Ltd. 2 Forward-looking statements disclaimer This presentation contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “predict,” “potential,” “continue,” “strategy,” “future,” “opportunity,” “would,” “seem,” “seek,” “outlook,” “goal,” “mission,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations, estimates, and assumptions and, as a result, are subject to risks and uncertainties that could cause actual results to differ materially from the expected results. These statements are based on various assumptions, whether or not identified in this presentation. These forward-looking statements may include, without limitation: Zura Bio’s clinical development plans; the design, initiation, conduct, enrollment and timing of its clinical trials; expectations regarding the timing of key milestones and anticipated data readouts; expectations regarding Zura Bio’s clinical programs, including the safety, efficacy, and therapeutic potential of Zura Bio’s product candidates; expectations regarding the commercial potential of Zura Bio’s product candidates; expectations regarding data readouts from third parties; expectations regarding market opportunities, competitive landscape, addressable patient populations, or potential clinical differentiation; Zura Bio’s cash resources and projected cash runway; Zura Bio’s business strategies and objectives; and any other statements that are not historical facts. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on, by an investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events are difficult or impossible to predict and could differ materially from those expressed or implied in such forward-looking statements, as a result of these risks and uncertainties, which include, but are not limited to: Zura Bio’s expectations regarding its product candidates and their related benefits, and Zura Bio’s beliefs regarding competing product candidates and products both in development and approved, may not be achieved; Zura Bio's vision and strategy may not be successful; the timing of key events and initiation of Zura Bio's studies, regulatory matters and release of clinical data may take longer than anticipated or may not be achieved at all; the potential general acceptability and maintenance of Zura Bio's product candidates by regulatory authorities, payors, physicians, and patients may not be achieved; Zura Bio's ability to attract and retain key personnel; Zura Bio's expectations with respect to its future operating expenses, capital requirements and needs for additional financing may not be achieved; Zura Bio has not completed any clinical trials, and has no products approved for commercial sale; Zura Bio has incurred significant losses since inception, and expects to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future; Zura Bio requires substantial additional capital to finance its operations, and if it is unable to raise such capital when needed or on acceptable terms, Zura Bio may be forced to delay, reduce, and/or eliminate one or more of its development programs or future commercialization efforts; Zura Bio may be unable to renew existing contracts or enter into new contracts; Zura Bio relies on third-party contract development manufacturing organizations for the manufacture of clinical materials; Zura Bio relies on contract research organizations, clinical trial sites, and other third parties to conduct its preclinical studies and clinical trials; Zura Bio may be unable to obtain regulatory approval for its product candidates, and there may be related restrictions or limitations of any approved products; Zura Bio may be unable to successfully respond to general economic and geopolitical conditions; Zura Bio may be unable to effectively manage growth; Zura Bio faces competitive pressures from other companies worldwide; Zura Bio may be unable to adequately protect its intellectual property rights; and other factors set forth in documents filed, or to be filed by Zura Bio, with the Securities andExchange Commission (SEC), including the risks and uncertainties described in the “Risk Factors” section of Zura Bio’s Annual Report on Form 10-K for the year ended December 31, 2025, and other filings with the SEC. These risks and uncertainties may be amplified by health epidemics or other unanticipated global disruption events, which may continue to cause economic uncertainty. Zura Bio cautions that the foregoing list of factors is not exclusive or exhaustive and not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Zura Bio gives no assurance that it will achieve its expectations. Zura Bio does not undertake or accept any obligation to update any forward-looking statements, whether as a result of new information, future developments, or otherwise, except as required by law. No assurance can be given that the expectations expressed herein will be achieved or that deviations from such expectations will not be material. This presentation discusses product candidates that are under clinical investigation and have not been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety, efficacy, or likelihood of regulatory approval of these product candidates for the uses under investigation. Comparisons across clinical trials or product candidates should be interpreted with caution, as differences in study design, inclusion/exclusion criteria, patient populations, endpoints, dosing regimens, and other variables may limit interpretability. Statements in this presentation regarding clinical trials involving product candidates originating from third parties (including Eli Lilly, Pfizer and Novartis) have not been reviewed, verified, or endorsed by such parties. |
| ©2026 Zura Bio Ltd. Zura Bio: advancing a differentiated approach for complex immune disorders Our lead program, tibulizumab, is the first and currently only in-class bispecific antibody inhibiting both the IL-17 and BAFF pathways Fusion of components from tabalumab, a BAFF-binding antibody, and an IL-17–binding single-chain variable fragment derived from ixekizumab (marketed as Taltz®, ~$3.6B in global 2025 sales, as reported) Potent engagement of targets and low immunogenicity observed in completed Phase 1 studies Tibulizumab has been rationally designed to address complex autoimmune diseases not fully addressed by single-pathway therapies Dual-pathway inhibition offers the potential to overcome efficacy ceilings observed with single-pathway inhibition Potential to modulate both B-cell– and T-cell–driven pathobiology Initial clinical focus on hidradenitis suppurativa (HS) and systemic sclerosis (SSc), each characterized by complex immune pathobiology involving both B- and T-cell activation HS: potential to be the best-in-class treatment by inhibiting two pathways already independently validated SSc: potential to be first-in-disease treatment able to treat both skin and lung manifestations, where both IL-17 and BAFF have been implicated Zura Bio is financed well beyond key near-term value inflection points Topline data expected from HS and SSc phase 2 studies in Q4 2026 and 1H 2027, respectively ~$109M in cash (as of December 31, 2025), plus $144M gross proceeds from public offering closed February 26, 2026 Capital expected to fund planned operations through at least the end of 2028 As a result of recent February 2026 public offering, ~124M shares outstanding (as-converted)* 3 Nasdaq: ZURA (*) Shares outstanding as of March 19, 2026; includes 21.2 million shares issued as part of February 2026 financing and ~29.3 million shares issuable upon conversion of outstanding pre-funded warrants to purchase Class A ordinary shares. This figure does not reflect potential dilution from outstanding stock options or unvested RSUs. Sources: Zura Bio Ltd., public filings and disclosures; Evaluate Pharma; publicly available information on ixekizumab (Taltz®) and tabalumab. Acronyms: BAFF, B-cell activating factor; HS, hidradenitis suppurativa; IL-17, interleukin-17; scFv, single-chain variable fragment; SSc, systemic sclerosis. |
| ©2026 Zura Bio Ltd. 4 Executive team and board of directors Amit Munshi Chairman Ajay Nirula, MD, PhD Director Dan Becker, MD, PhD Director Jennifer Jarrett Director Mark Eisner, MD, MPH Director Parvinder Thiara Director Someit Sidhu, MD Co-Founder & Director Steve Schoch Director Sandeep Kulkarni, MD Co-Founder, CEO & Director Board of directors Nasdaq: ZURA Kim Davis, JD Chief Operating Officer, Chief Legal Officer and Corporate Secretary Eric Hyllengren Chief Financial Officer Gary Whale, PhD Chief Technology Officer Kiran Nistala, MBBS, PhD Chief Medical Officer and Head of Development Sandeep Kulkarni, MD Co-Founder, Chief Executive Officer and Director Executive Team |
| Sources: ClinicalTrials.gov ID NCT06993610; ClinicalTrials.gov ID NCT06843239. ©2026 Zura Bio Ltd. Acronyms: HS, hidradenitis suppurativa; SSc, systemic sclerosis. 5 Two ongoing Phase 2 trials targeting high unmet need in multi-pathway autoimmune diseases Nasdaq: ZURA A Phase 2 trial in adults with HS Anticipated readout: Q4 2026 A Phase 2 trial in adults with SSc Anticipated readout: 1H 2027 Optionality for pipeline expansion into additional autoimmune indications with complex immune pathobiology |
| ©2026 Zura Bio Ltd. Limits of monotherapy in multi-pathway autoimmune disease Acronyms: HS, hidradenitis suppurativa; SSc, systemic sclerosis. 6 Nasdaq: ZURA Implication: these limitations support therapeutic approaches designed to address more than one disease-driving pathway with a single agent Autoimmune diseases, including HS and SSc, are driven by multiple, intersecting immune pathways, resulting in biological heterogeneity across patients Single-pathway biologics may deliver low or inadequate response rates in complex autoimmune diseases Even among responders, pathway redundancy and compensatory signaling can limit depth and durability of response with monotherapy |
| ©2026 Zura Bio Ltd. Tibulizumab: a single-molecule dual-pathway approach Tibulizumab is an investigational agent. Its efficacy and safety have not been established or approved by the FDA or any regulatory agency worldwide. Sources: ClinicalTrials.gov ID NCT06993610; ClinicalTrials.gov ID NCT06843239; Publicly available information on ixekizumab and tabalumab; Benschop et al., mAbs (2019), DOI: 10.1080/19420862.2019.1624463. Acronyms: Ab, antibody; BAFF, B-cell activating factor; HS, hidradenitis suppurativa; IL-17, interleukin-17; IL-17A/F, interleukin-17A/interleukin-17F heterodimer; scFv, single-chain variable fragment; SSc, systemic sclerosis. 7 Nasdaq: ZURA Addresses disease complexity: aims to target two distinct immune pathways implicated in chronic inflammation and autoimmunity Clinically grounded design: fusion of a BAFF-binding antibody (tabalumab) with the IL-17A-binding scFv from ixekizumab Single-entity advantage: enables dual-pathway modulation without multi-drug combination complexity ixekizumab Anti-IL-17 scFv IL-17A & IL-17A/F tabalumab Anti-BAFF Ab BAFF tibulizumab Tetravalent bispecific antibody designed to block BAFF and IL-17A–mediated signaling, including IL-17A/F heterodimers Inhibition of BAFF and IL-17A in one bispecific antibody |
| ©2026 Zura Bio Ltd. Phase 1/1b data support advancement of tibulizumab into Phase 2 development 8 Tibulizumab is an investigational agent. Its efficacy and safety have not been established or approved by the FDA or any regulatory agency worldwide. (*) Model-predicted median maximum percent change from baseline of free unbound BAFF and IL-17 following the last dose. Values shown reflect steady-state trough suppression. Sources: Eli Lilly and Company–conducted Phase 1/1b clinical studies; Zura Bio Ltd. internal clinical study reports (CSRs). Acronyms: ADA, anti-drug antibody; BAFF, B-cell activating factor; CFB, change from baseline; CRP, C-reactive protein; IL-17, interleukin-17; PD, pharmacodynamics; PK, pharmacokinetics; Q4W, once every 4 weeks. Nasdaq: ZURA 78 participants dosed across Phase 1/1b studies >98% median trough target engagement for both IL-17 and BAFF in peripheral blood at 300 mg Q4W Mean terminal half-life (t½): 26.9 days, supporting once-monthly dosing Pharmacodynamic activity observed, including B cell and CRP reductions Low incidence of treatment-emergent ADAs in multiple-dose cohorts Safety profile consistent with published IL-17 and BAFF pathway experience, with no new or unexpected safety signals to date Time (weeks) Free BAFF concentration %CFB Free IL-17 concentration %CFB 100 mg Q4W 300 mg Q4W 100 mg Q4W 300 mg Q4W Population prediction interval* Median free target concentration Dose-dependent and comparable BAFF and IL-17 target engagement Model-based PK/PD analysis demonstrates a clear exposure–response relationship, with comparable BAFF and IL-17 suppression and near-complete target engagement at higher doses |
| ©2026 Zura Bio Ltd. BAFF: a clinically validated immune pathway central to B cell survival 9 Sources: Vincent, F.B. et al. (2013), Cytokine & Growth Factor Reviews, DOI:10.1016/j.cytogfr.2013.04.003; Smulski, C.R. and Eibel, H. (2018), Frontiers in Immunology, DOI:10.3389/fimmu.2018.02285; Matsushita, T. et al. (2005), Arthritis & Rheumatism, DOI:10.1002/art.21526.; Sabat, R. et al. (2023), Journal of Allergy and Clinical Immunology, DOI:10.1016/j.jaci.2022.10.034. Acronyms: Ab, antibody; BAFF, B-cell activating factor; HS, hidradenitis suppurativa; IL-17, interleukin-17; IL-17A/F, interleukin-17A/interleukin-17F heterodimer; scFv, single-chain variable fragment; SSc, systemic sclerosis. Nasdaq: ZURA BAFF represents a clinically validated immune pathway addressing a fundamental driver of chronic autoimmune disease biology BAFF is a non-redundant survival factor supporting persistence and differentiation of autoreactive B cells Genetic, translational, and clinical data show that disruption of BAFF signaling leads to marked reductions in peripheral B cells Elevated BAFF levels and B cell dysregulation are reported across immune-mediated diseases, including HS and SSc BAFF inhibition targets a core B cell survival pathway distinct from IL-17–mediated inflammatory signaling ixekizumab Anti-IL-17 scFv tabalumab Anti-BAFF Ab BAFF tibulizumab Tetravalent bispecific antibody designed to block BAFF and IL-17A–mediated signaling, including IL-17A/F heterodimers |
| ©2026 Zura Bio Ltd. IL-17A: a clinically validated inflammatory pathway 10 Notes: The IL-17A-binding domain of tibulizumab is derived from ixekizumab. Sources: Gaffen, S.L. et al. (2014), Nature Reviews Immunology, DOI:10.1038/nri3707; Griffiths, C.E. et al. (2015), The Lancet, DOI:10.1016/s0140-6736(15)60125-8; Blauvelt, A. et al. (2021), Journal of the American Academy of Dermatology, DOI:10.1016/j.jaad.2020.11.022; Eli Lilly and Company, ixekizumab (Taltz®) Prescribing Information. Acronyms: Ab, antibody; BAFF, B-cell activating factor; IL-17, interleukin-17; IL-17A, interleukin-17A; IL-17A/F, interleukin-17A/interleukin-17F heterodimer; scFv, single-chain variable fragment. IL-17A represents a clinically validated inflammatory pathway in autoimmune disease, with approvals in rheumatology and dermatology Nasdaq: ZURA IL-17 is a central amplifier of inflammation across multiple immune-mediated diseases IL-17 pathway inhibition has demonstrated efficacy across multiple inflammatory indications, supported by extensive clinical experience Ixekizumab represents a well-established clinical benchmark for IL-17 pathway inhibition, blocking IL-17A and IL-17A/F signaling ixekizumab Anti-IL-17 scFv tabalumab Anti-BAFF Ab tibulizumab IL-17A & IL-17A/F Tetravalent bispecific antibody designed to block BAFF and IL-17A–mediated signaling, including IL-17A/F heterodimers |
| ©2026 Zura Bio Ltd. Ixekizumab: a high-efficacy clinical benchmark for IL-17 pathway inhibition Consistent high efficacy: Demonstrated across multiple inflammatory diseases in large Phase 3 programs* Validated IL-17 pathway inhibition: Neutralization of IL-17A and IL-17A/F produces robust clinical responses with a well-characterized safety profile Extensive clinical experience: Supported by large global clinical development programs and post-marketing datasets across dermatologic and rheumatologic indications* (*) PASI 90 values represent placebo-adjusted response rates at Week 12 from independent Phase 3 psoriasis trials. Studies were not designed for head-to-head comparison; trial designs, patient populations, dosing regimens, and placebo response rates differed. Clinical efficacy data shown are limited to psoriasis studies. Efficacy and durability may vary by indication. Sources: Griffiths, C.E. et al. (2015), The Lancet, DOI:10.1016/s0140-6736(15)60125-8; Langley, R.G. et al. (2014), New England Journal of Medicine, DOI:10.1056/nejmoa1314258; Gordon, K.B. et al. (2016), New England Journal of Medicine, DOI:10.1056/nejmoa1512711; Eli Lilly and Company and Novartis public disclosures and prescribing information. Acronyms: IL-17, interleukin-17; IL-17A, interleukin-17A; IL-17A/F, interleukin-17A/interleukin-17F heterodimer; PASI 90, Psoriasis Area and Severity Index 90% improvement; PBO, placebo; PsO, psoriasis. 11 Ixekizumab establishes a well-characterized clinical benchmark for IL-17 pathway inhibition Multiple Phase 3 programs completed High efficacy demonstrated Broad IL-17 pathway inhibition Extensive clinical and real-world experience Nasdaq: ZURA secukinumab PASI 90 at Week 12* (Phase 3 psoriasis studies) PASI 90 (%; PBO-adjusted) 0 10 20 30 40 50 60 70 80 ixekizumab UNCOVER-1 UNCOVER-2 UNCOVER-3 PsO1 PsO2 |
| ©2026 Zura Bio Ltd. 12 (*) Clinical studies have shown higher rates of mucocutaneous candidiasis with broader IL-17 pathway inhibition that includes IL-17F. Sources: Benschop, R.J. et al. (2019), mAbs, DOI:10.1080/19420862.2019.1624463; Adams, R. et al. (2020), Frontiers in Immunology, DOI:10.3389/fimmu.2020.01894. Acronyms: BAFF, B-cell activating factor; HS, hidradenitis suppurativa; IL, interleukin; IL-17A, interleukin-17A; IL-17F, interleukin-17F; IL-17A/A, interleukin-17A homodimer; IL-17A/F, interleukin-17A/interleukin-17F heterodimer; IL-17F/F, interleukin-17F homodimer; KD, dissociation constant; mAb, monoclonal antibody; pM, picomolar. Tibulizumab is the first and only in-class bispecific antibody targeting IL-17 and BAFF IL-17 pathway B-Cell–driven inflammation Agent Target description IL-17A/A (KD) IL-17A/F (KD) IL-17F/F* (KD) Tibulizumab Anti-BAFF & IL-17 bispecific mAb ~14 pM ~90 pM no binding BAFF Secukinumab (Cosentyx®) Anti-IL-17A mAb ~60–90 pM ~2400 pM no binding no Bimekizumab (Bimzelx®) Anti-IL-17A/F mAb ~3.2 pM ~26 pM ~23 pM no Nasdaq: ZURA IL-17–only approaches Inhibits IL-17A signaling with varying affinity May also inhibit IL-17A/F or IL-17F to further suppress the IL-17 pathway Does not address additional disease drivers Tibulizumab (anti-IL-17 + BAFF) Inhibits key IL-17 ligands (IL-17A/A and IL-17A/F) Adds BAFF pathway inhibition (B-cell biology) Is designed to address multiple disease drivers |
| ©2026 Zura Bio Ltd. Tibulizumab targets two potentially high-value autoimmune market opportunities 13 Nasdaq: ZURA Note: Market estimates based on third-party analyses and published literature, including DRG/Clarivate, Evaluate Pharma, GlobalData, peer-reviewed epidemiology studies, and company analyses. Acronyms: TAM, total addressable market. Potential significant multi-billion-dollar market opportunities Growing biologics market supported by increasing diagnosis and utilization Chronic inflammatory disease with durable treatment demand and high unmet need Heterogeneous disease biology creates opportunity beyond single-pathway approaches Large and expanding chronic disease HIDRADENITIS SUPPURATIVA ~$8B projected by the mid-2030s ESTIMATED TAM Rare autoimmune disease with significant unmet need and limited effective treatment options Specialist-managed market with concentrated prescribing and premium pricing dynamics Multisystem inflammatory and fibrotic manifestations contribute to substantial disease burden High-value orphan autoimmune opportunity SYSTEMIC SCLEROSIS ~$4B projected by mid-2030s ESTIMATED TAM |
| ©2026 Zura Bio Ltd. A dual-pathway approach in HS tibulizumab ZB-106 Anti-BAFF + IL-17 First and currently only in-class bispecific antibody designed to target BAFF and IL-17 signaling, including IL-17A and IL-17A/F Phase 2 clinical trial (TibuSHIELD) ongoing; topline data anticipated in Q4 2026 Tibulizumab is an investigational agent. Its efficacy and safety have not been established or approved by the FDA or any other regulatory agency worldwide. |
| Nasdaq: ZURA | www.zurabio.com HS is a complex and relapsing disease ©2026 Zura Bio Ltd. The interplay of acute lesions, chronic inflammation, and complex immune drivers makes HS uniquely challenging, and highlights the opportunity for biology-driven solutions Patient experience HS affects ~1% of the population and is widely underdiagnosed Painful nodules and abscesses form in sensitive areas Lesions may progress to tunnels and scarring Acute flares coexist with chronic inflammation Delayed diagnosis and variable treatment response Underlying biology HS lesions are driven by a diverse, dynamic immune microenvironment Prominent immune signatures: Th1/Th17, neutrophils, B cells Chronic immune activity underlies persistent, relapsing disease course Sources: Moran, B. et al. (2017), Journal of Investigative Dermatology, DOI:10.1016/j.jid.2017.05.033; Banerjee, A. et al. (2017), Immunological Investigations, doi:10.1080/08820139.2016.1230867; Sabat, R. et al. (2023), Journal of Allergy and Clinical Immunology, DOI:10.1016/j.jaci.2022.10.034; Garg, A. et al. (2017), JAMA Dermatology, DOI:10.1001/jamadermatol.2017.0201; Ingram, J.R. (2020), British Journal of Dermatology, DOI:10.1111/bjd.19435; Midgette, B. et al. (2022), British Journal of Dermatology, DOI:10.1111/bjd.21798; Sabat, R. et al. (2020), Nature Reviews Disease Primers, DOI:10.1038/s41572-020-0149-1; MEDACorp key opinion leader (KOL) discussions. Acronyms: HS, hidradenitis suppurativa; Th1, T helper 1 cell; Th17, T helper 17 cell. tibulizumab | ZB-106 15 |
| ©2026 Zura Bio Ltd. A dual-pathway approach to hidradenitis suppurativa 16 Targeting immune drivers of chronic inflammation and tissue damage Disease Chronic, inflammatory skin disease with recurrent painful lesions Significant impact on quality of life and long-term morbidity Biology Heterogeneous disease driven by activation of multiple immune pathways BAFF elevation and associated B cell dysregulation observed in HS lesions IL-17A–driven inflammation implicated in dysfunction of neutrophils, macrophages, and keratinocytes Program Tibulizumab (BAFF + IL-17A bispecific antibody) Phase 2 TibuSHIELD clinical study in adults with HS; topline data expected Q4 2026 Th17 cell IL-17A IL-17A B cell tibulizumab | ZB-106 Acronyms: BAFF, B cell activating factor; HS, hidradenitis suppurativa; IL-17A, interleukin-17A; Th17, T helper 17 cells. |
| ©2026 Zura Bio Ltd. Neutrophils and B cells represent orthogonal immune drivers in HS Sources: Rumberger, B.E. et al. (2020), Inflammation Research, DOI:10.1007/s00011-020-01381-7; Sabat, R. et al. (2023), Journal of Allergy and Clinical Immunology, doi:10.1016/j.jaci.2022.10.034; Macchiarella, G. et al. (2023), Journal of Investigative Dermatology, DOI:10.1016/j.jid.2022.08.051; Gudjonsson, J.E. et al. (2020), JCI Insight, doi:10.1172/jci.insight.139930; Rastrick, J. et al. (2024), British Journal of Dermatology, DOI:10.1093/bjd/ljae442. Acronyms: BAFF, B-cell activating factor; B cell, B lymphocyte; HS, hidradenitis suppurativa; IL-17, interleukin-17; IL-17A, interleukin-17A; NETosis, neutrophil extracellular trap formation; T cell, T lymphocyte; TLS, tertiary lymphoid structure. 17 IL-17 and BAFF act through distinct pathways that drive neutrophil- and B cell–mediated immune pathology in HS Neutrophils: Abundant in HS lesions and sinus tracts Amplify acute inflammatory flares and tissue damage Driven in part by IL-17A–mediated recruitment and activation B cells: Activated and persistent in HS lesions Contribute to chronic immune activation Supported by BAFF-mediated survival and pro-inflammatory functions tibulizumab | ZB-106 Neutrophils and B cells are rare in healthy skin but infiltrate HS lesions |
| ©2026 Zura Bio Ltd. IL-17A– and B cell–associated pathways contribute to inflammation in HS Sources: Novartis, AAD Annual Meeting 2024; ClinicalTrials.gov ID NCT03827798; Sabat, R. et al. (2023), Journal of Allergy and Clinical Immunology, DOI:10.1016/j.jaci.2022.10.034; Macchiarella, G. et al. (2023), Journal of Investigative Dermatology, DOI:10.1016/j.jid.2022.08.051. Acronyms: BAFF, B cell activating factor; BAFF-R, B cell activating factor receptor; BTK, Bruton’s tyrosine kinase; HS, hidradenitis suppurativa; IL-17, interleukin-17; IL-17A, interleukin-17A. 18 HS is characterized by IL-17A–mediated inflammation, with emerging clinical evidence supporting B cell– pathways, underscoring the approach for multi-pathway strategies B cells and plasma cells infiltrate acute and chronic HS lesions and contribute to persistent immune activation BAFF expression aligns with B-cell and plasma-cell signatures in human HS tissue Elevated BAFF provides a biological link between B-cell accumulation and chronic immune persistence Clinical activity observed with multiple B cell–targeted approaches in HS, including BTK inhibition (remibrutinib) and BAFF-R inhibition (ianalumab) B cell / BAFF-associated biology Emerging clinical evidence Elevated IL-17 pathway activity observed in HS lesions Amplifies macrophage and neutrophil-driven inflammation and keratinocyte activation Clinical efficacy demonstrated with IL-17 pathway inhibitors IL-17A biology Clinically validated tibulizumab | ZB-106 |
| ©2026 Zura Bio Ltd. Increasing clinical evidence for B cell–related pathways in hidradenitis suppurativa* 19 tibulizumab | ZB-106 (*) Data derived from a randomized, placebo-controlled, multi-arm hidradenitis suppurativa platform study (ClinicalTrials.gov Identifier: NCT03827798). Reported results are based on information posted on ClinicalTrials.gov (as of 09-Jan-2026) and are subject to sponsor quality review and potential update. Results are descriptive and not powered for formal cross-arm comparisons. (**) sHiSCR50: ≥50% reduction in abscess and inflammatory nodule count, with no increase in abscesses or draining fistulas, assessed using a simplified lesion-count methodology. Sources: Novartis, AAD Annual Meeting 2024; ClinicalTrials.gov ID: NCT03827798. Acronyms: BAFF-R, B-cell activating factor receptor; BTK, Bruton’s tyrosine kinase; CD40, cluster of differentiation 40; HS, hidradenitis suppurativa; IL-1 interleukin-1 beta; IL-18, interleukin-18; LPA1, lysophosphatidic acid receptor 1; sHiSCR50, Simplified Hidradenitis Suppurativa Clinical Response (50%). β, 72.7% 48.5% 58.6% 51.6% 46.9% 32.0% 36.0% remibrutinib (LOU064) BTKi 25 mg remibrutinib (LOU064) BTKi 100 mg iscalimab (CFZ533) anti-CD-40 ianalumab (VAY736) BAFF-R MAS825 IL-1β / IL-18 LYS006 LPA1 Pooled placebo (contemporaneous cohorts) Observed sHiSCR50** Responders at Week 16 by Treatment Arm (Observed response rates; non-responder imputation applied) Observations: Data show that B-cell–associated pathways (BTK, BAFF-R, CD40) demonstrate numerically higher sHiSCR50 response rates than pooled placebo in this HS platform study. BAFF-R inhibition (ianalumab) shows numerically meaningful observed activity, supporting a potential role for B-cell survival pathways in HS. IL-1β / IL-18 inhibition (MAS825) shows more modest observed activity with limited separation from pooled placebo. |
| ©2026 Zura Bio Ltd. HS landscape: multiple approved and late-stage therapies highlight ongoing need for differentiation 20 tibulizumab | ZB-106 Company Asset Tibulizumab (ZB-106) Adalimumab (Humira®) Secukinumab (Cosentyx®) Bimekizumab (Bimzelx®) Sonelokimab Remibrutinib Brivekimig (SAR444245) AVTX-009 Lutikizumab (ABT-981) Zasocitinib (TAK-279) Mechanism of Action Anti-BAFF and IL-17 bispecific mAb Anti-TNFα mAb Anti-IL-17A mAb Anti-IL-17A /F mAb Anti-IL-17A/F Nanobody Covalent BTK inhibitor TNFα / OX40L bispecific mAb Anti-IL-1β mAb IL-1α / IL-1β mAb TYK2 inhibitor Stage of Development Phase 2 Approved Approved Approved Phase 3 Phase 3 Phase 2 Phase 2 Phase 3 Phase 2 Route of Administration SC SC SC SC SC PO SC SC SC PO Dosing Frequency Q4W (studied) Q2W–Q4W Q4W Q2W → Q4W Q2W / Q4W (studied) QD Q4W (studied) Q2W–Q4W QW–Q2W QD Note: Approved and development status reflect HS or broader inflammatory indications as publicly reported; dosing regimens shown represent studied or labeled schedules and may vary by program. Table is descriptive and not intended to imply direct comparison between products. Sources: Company public disclosures, prescribing information, conference presentations, and ClinicalTrials.gov. Acronyms: BAFF, B cell activating factor; BTK, Bruton’s tyrosine kinase; HS, hidradenitis suppurativa; IL-1α, interleukin-1 alpha; IL-1β, interleukin-1 beta; IL-17, interleukin-17; IL-17A, interleukin-17A; IL-17A/F, interleukin-17A/interleukin-17F heterodimer; IV, intravenous; mAb, monoclonal antibody; OX40L, OX40 ligand; PO, oral administration; QD, once daily; QW, once weekly; Q2W, once every two weeks; Q4W, once every four weeks; SC, subcutaneous; TNFα, tumor necrosis factor alpha; TYK2, tyrosine kinase 2. |
| ©2026 Zura Bio Ltd. 21 (*) Includes secondary and exploratory endpoints Acronyms: AN, abscess and inflammatory nodule; DLQI, Dermatology Life Quality Index; HiSCR50, Hidradenitis Suppurativa Clinical Response ≥50%; HiSCR75, Hidradenitis Suppurativa Clinical Response ≥75%; HS, hidradenitis suppurativa; IHS4, International Hidradenitis Suppurativa Severity Score System; NRS, Numeric Rating Scale; OLE, open-label extension; PK, pharmacokinetics; PD, pharmacodynamics; SC, subcutaneous; TNF-α, tumor necrosis factor alpha. tibulizumab | ZB-106 KEY INCLUSION CRITERIA PLANNED EFFICACY ENDPOINTS PRIMARY ENDPOINT Percent change from baseline in AN count at Week 16 ADDITIONAL ENDPOINTS* HiSCR50 and HiSCR75 Draining Tunnel Count IHS4 DLQI Skin pain NRS PK/PD assessments Other symptom and lesion-based measures per protocol Adults with moderate-to-severe HS, defined as: – Hurley Stage II/III (up to 40% Stage III allowed) – Total abscess and inflammatory nodule (AN) count ≥5 Up to 30% of participants may have prior TNF-α inhibitor exposure Additional eligibility criteria per protocol Randomized, double-blind, placebo-controlled, three-arm study 16-week primary efficacy period followed by a 16-week OLE Tibulizumab dose: 150 mg and 300 mg SC Dose selection informed by Phase 1 PK/PD and target engagement data Efficacy Period (16 weeks) OLE (16 weeks) Study timeline (weeks) 1:1:1 R tibulizumab (n ≈ 75) 150 mg n ≈ 225 placebo (n ≈ 75) participants tibulizumab (n ≈ 75) 300 mg tibulizumab 150 mg 0 2 4 8 12 16 20 24 28 32 Week 32 Final OLE study visit (no SC dose) SC dosing at study visit = Phase 2 study in moderate-to-severe hidradenitis suppurativa |
| ©2026 Zura Bio Ltd. A dual-pathway approach in SSc tibulizumab ZB-106 Anti-BAFF + IL-17 First and currently only in-class bispecific antibody designed to target BAFF and IL-17 signaling, including IL-17A and IL-17A/F Phase 2 clinical trial (TibuSURE) ongoing; topline data anticipated in 1H 2027 Tibulizumab is an investigational agent. Its efficacy and safety have not been established or approved by the FDA or any other regulatory agency worldwide. |
| ©2026 Zura Bio Ltd. Systemic sclerosis is a progressive, multisystem autoimmune disease with limited therapeutic options* (*) Two therapies are approved for SSc-ILD; however, no treatment approved for SSc addresses multiple organ systems. Sources: Clarivate/DRG (accessed 19 August 2024); public regulatory disclosures and prescribing information. Acronyms: CGA, Clinical Global Assessment; EU5, five major European markets (France, Germany, Italy, Spain, United Kingdom); FVC, forced vital capacity; HAQ-DI, Health Assessment Questionnaire Disability Index; ILD, interstitial lung disease; mRSS, modified Rodnan Skin Score; PtGA, Patient Global Assessment; SSc, systemic sclerosis; US, United States. 23 Systemic Sclerosis (SSc) is a Rare, Serious Multisystem Autoimmune Disease No therapies are approved that comprehensively address the multisystem pathology of SSc* ~300,000 people are estimated to be living with SSc across major markets (US, EU5, Japan) TibuSURE Phase 2 Trial Evaluates Key Domains of Systemic Sclerosis Other Organs Heart Kidney Liver Stomach SSc-ILD is a major cause of morbidity and mortality in SSc. Two disease-modifying treatments are approved for SSc-ILD Lungs Skin Characterized by Chronic Inflammation and Fibrosis Across Organs Skin fibrosis contributes to functional impairment, disability, and reduced quality of life FVC Forced Vital Capacity mRSS modified Rodnan Skin Score HAQ-DI Health Assessment Questionnaire Disability Index PtGA Patient Global Assessment CGA Clinical Global Assessment Lung Function Skin Fibrosis Functional Impact Patient-Reported Outcome Clinician-Reported Outcome tibulizumab | ZB-106 |
| ©2026 Zura Bio Ltd. A dual-pathway approach in systemic sclerosis 24 Targeting immune drivers of autoimmunity, inflammation, and fibrosis Disease Severe, progressive, multisystem autoimmune disease Core features: inflammation, vasculopathy, and fibrosis No therapies are approved that comprehensively address the multisystem pathology of SSc* Program Tibulizumab (BAFF + IL-17A bispecific antibody) Phase 2 TibuSURE clinical study; topline data expected 1H 2027 Biology Inflammation plays a key role in fibrosis and vasculopathy Autoreactive B cells and autoantibodies are key inflammatory signature IL-17 pathway elevation observed in SSc patients Th17 cell IL-17A IL-17A B cell (*) Two therapies are approved for SSc-ILD; however, no treatment approved for SSc addresses multiple organ systems. Acronyms: BAFF, B cell activating factor; IL-17A, interleukin-17A; SSc, systemic sclerosis; Th17, T helper 17 cells. tibulizumab | ZB-106 |
| ©2026 Zura Bio Ltd. IL-17A and BAFF/B cells contribute to inflammation, vasculopathy, and fibrosis in systemic sclerosis Core Disease Features SSc is characterized by chronic inflammation, vasculopathy, and progressive fibrosis Infiltration of activated immune cells (macrophages, T cells, B cells) creates a persistent inflammatory tissue environment BAFF / B Cell Biology BAFF is elevated in SSc and supports survival and activation of autoreactive B cells Activated B cells produce autoantibodies and inflammatory cytokines (e.g., IL-6) associated with fibrosis and vascular dysfunction IL-17A Biology IL-17A has been reported to be elevated in subsets of patients with SSc Preclinical studies suggest IL-17A can activate fibroblasts and endothelial cells, promoting inflammation, immune cell recruitment, and tissue remodeling 25 tibulizumab | ZB-106 Sources: Seki, N. et al. (2024), Cytokine, DOI:10.1016/j.cyto.2024.156534; Ono, Y. et al. (2024), Scientific Reports, DOI:10.1038/s41598-024-76987-6; Lonati, P.A. et al. (2014), PLoS ONE, DOI:10.1371/journal.pone.0105008; Deng, C.-C. et al. (2025), Frontiers in Immunology, DOI:10.3389/fimmu.2024.1522076; Kurasawa, K. et al. (2000), Arthritis & Rheumatism, 43(11), pp. 2455– 2463. doi:10.1002/1529-0131(200011)43:11<2455::aid-anr12>3.0.co;2-k. Acronyms: BAFF, B cell activating factor; IL-6, interleukin-6; IL-17A, interleukin-17A; SSc, systemic sclerosis. |
| ©2026 Zura Bio Ltd. Targeting interconnected immune pathways in systemic sclerosis 26 BAFF- and IL-17–driven inflammation may contribute to vasculopathy and fibrosis, supporting evaluation of multi-pathway therapeutic strategies in SSc BAFF signaling supports survival of autoreactive B cells Elevated autoantibody production and cytokine networks (including IL-6, IL-17) are observed in SSc Immune-mediated endothelial dysfunction contributes to impaired blood flow Inflammatory cytokines (IL-6, IL-17) thought to promote immune cell infiltration and vascular injury Fibroblast activation contributes to progressive tissue fibrosis Excess extracellular matrix deposition (e.g., collagen) is characteristic of SSc INFLAMMATION VASCULOPATHY FIBROTIC REMODELING Sources: Allanore, Y. et al. (2015), Nature Reviews Disease Primers, DOI:10.1038/nrdp.2015.2; Distler, J.H. et al. (2019), Nature Reviews Rheumatology, DOI:10.1038/s41584-019-0322-7; Asano, Y. and Sato, S. (2015), Seminars in Immunopathology, DOI:10.1007/s00281-015-0505-5; Varga, J. and Abraham, D. (2007), Journal of Clinical Investigation, DOI:10.1172/jci31139. Acronyms: BAFF, B cell activating factor; IL-6, interleukin-6; IL-17, interleukin-17; SSc, systemic sclerosis. tibulizumab | ZB-106 |
| ©2026 Zura Bio Ltd. Separately inhibiting IL-17A or BAFF has shown efficacy in placebo-controlled trials for systemic sclerosis Sources: Fukasawa, T. et al. (2022), Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2022-eular.2519; ClinicalTrials.gov ID NCT03957681; Gordon, J.K. et al. (2018), Arthritis & Rheumatology, DOI:10.1002/art.40358; ClinicalTrials.gov ID NCT01670565. Acronyms: BAFF, B cell activating factor; dcSSc, diffuse cutaneous systemic sclerosis; FVC, forced vital capacity; IL-17A, interleukin-17A; IIT, investigator-initiated trial; mRSS, modified Rodnan Skin Score; MMF, mycophenolate mofetil; NS, not significant; QOL, quality of life; SHAQ-DI, Scleroderma Health Assessment Questionnaire–Disability Index; SSc, systemic sclerosis; VAS, visual analog scale. 27 IL-17 RECEPTOR ANTAGONIST – PHASE 3 Brodalumab Met the primary endpoint of reduced mRSS at Week 24 for skin involvement, and demonstrated improvement in FVC as a secondary endpoint reflecting lung function Also showed therapeutic effects on lung/respiratory functions, digital ulcers, symptoms of gastroesophageal reflux disease, and QOL without noteworthy safety concerns Δ -21.2 units Δ +5.2% CLINICAL PRECEDENT Phase 3 brodalumab trial (24 weeks) mRSS FVC (% predicted) BAFF ANTAGONIST Belimumab In a 52-week, investigator-initiated, single-center, double-blind, placebo-controlled pilot trial involving 20 participants with dcSSc on background MMF Both treatment groups experienced improvements in mRSS, favoring belimumab (-10 vs. -3; p = NS) Secondary endpoints were met with statistical significance in two endpoints: SHAQ-DI and VAS Raynaud’s phenomenon CLINICAL PRECEDENT Phase 2 belimumab IIT trial (52 weeks) mRSS FVC (% predicted) Δ -7.0 units Δ +7.0% tibulizumab | ZB-106 |
| ©2026 Zura Bio Ltd. 28 (*) Includes secondary and exploratory endpoints Acronyms: CRISS, Combined Response Index in Systemic Sclerosis; FVC, forced vital capacity; HAQ-DI, Health Assessment Questionnaire Disability Index; HRCT, high-resolution computed tomography; ILD, interstitial lung disease; mRSS, modified Rodnan Skin Score; OLE, open-label extension; PK/PD, pharmacokinetics/pharmacodynamics; qHRCT, quantitative high-resolution computed tomography; R, randomization; SC, subcutaneous; SSc, systemic sclerosis. Phase 2 study in diffuse cutaneous systemic sclerosis KEY INCLUSION CRITERIA PLANNED EFFICACY ENDPOINTS PRIMARY ENDPOINT Change from baseline in mRSS at Week 24 ADDITIONAL ENDPOINTS* qHRCT lung imaging FVC HAQ-DI revised CRISS (rCRISS) Adults (18–75 years) with early diffuse cutaneous SSc, enriched for SSc-ILD Stable background immunosuppressive or antifibrotic therapy Anti-centromere antibody negative Disease duration ≤ 7 years mRSS 15–45 at screening Additional eligibility criteria per protocol Randomized, double-blind, placebo-controlled design 24-week primary efficacy period, followed by 28-week OLE Tibulizumab dose: 300 mg SC Dose selection informed by Phase 1 PK/PD and target engagement data tibulizumab | ZB-106 n ≈ 80 participants Efficacy Period (24 weeks) Baseline image HRCT 1:1 R tibulizumab (n ≈ 40) 300 mg placebo (n ≈ 40) OLE (28 weeks) tibulizumab 300 mg HRCT HRCT Week 52 (no SC dose) 0 2 4 8 12 16 20 24 28 32 36 40 44 48 52 Study timeline SC dosing (weeks) at study visit = |
| ©2026 Zura Bio Ltd. modified Rodnan Skin Score (mRSS): Endpoint for assessing skin thickness and fibrosis 29 Severe skin thickening and tightening restricts movement and causes painful ulcers on the hands and fingers, significantly impairing daily activities and quality of life. vs Fine Wrinkles (0/3) Severe Thickness (3/3) The mRSS assesses skin thickness in systemic sclerosis patients by evaluating 17 body sites (e.g., face, chest, abdomen, arms, legs). Each site is scored from 0 to 3. The total score ranges from 0 to 51, with higher scores indicating greater skin involvement. 17 Surface Anatomic Areas of the Body 2 Moderate Thickness 1 Mild Thickness 3 Severe Thickness 0 Normal Skin Face Anterior chest Abdomen Upper arm Forearm Hand Fingers Thigh Leg Foot Upper arm Forearm Hand Fingers Thigh Leg Foot with inability to pinch the skin into a fold Sources: Khanna, D. et al. (2017), Journal of Scleroderma and Related Disorders, doi:10.5301/jsrd.5000231; Ferreli, C. et al. (2018), Clinical Reviews in Allergy & Immunology, doi:10.1007/s12016-017-8625-4. tibulizumab | ZB-106 |
| ©2026 Zura Bio Ltd. In phase 2, lung involvement using qHRCT is a key secondary endpoint 30 Sources: Goldin, J. et al. (2018), Annals of the American Thoracic Society, doi:10.1513/annalsats.201802-079OC; Zura Bio internal planning. Acronyms: ILD, interstitial lung disease; MMF, mycophenolate mofetil; qHRCT, quantitative high-resolution computed tomography; QILD, quantitative interstitial lung disease; QLF, quantitative lung fibrosis; SSc, systemic sclerosis. ILD includes various pulmonary disorders marked by inflammation and progressive lung fibrosis, resulting in restrictive lung function and impaired gas exchange. SSc often leads to ILD due to immune system dysregulation and subsequent lung interstitial fibrosis. vs Healthy Lung Fibrotic Lung QILD by HRCT provides a sensitive measure of lung involvement, detecting changes as small as 2%. Example of improvement after 24 months of MMF in total lung involvement The blue and red areas show QLF, while the yellow area shows quantitative ground glass. The entire colored area represents QILD. After 24 months, QLF areas decreased (arrow in B). tibulizumab | ZB-106 |
| ©2026 Zura Bio Ltd. Key takeaways Clear differentiation Tibulizumab is the first and currently only in-class bispecific antibody designed to simultaneously target BAFF and IL-17– mediated signaling, addressing immune complexity beyond single-pathway approaches 31 Acronyms: BAFF, B cell activating factor; IL-17, interleukin-17. Defined, anticipated near-term clinical catalysts Two independent Phase 2 trials (TibuSHIELD and TibuSURE) evaluating a dual-pathway strategy in diseases with significant unmet need and potential multi-billion dollar market opportunities Platform optionality Multi-pathway immune biology provides potential for expansion into additional autoimmune indications, subject to clinical validation Nasdaq: ZURA |
FAQ
How did Zura Bio (ZURA) perform financially in full-year 2025?
What is Zura Bio’s cash position and runway after its 2026 financing?
What are the key clinical milestones for Zura Bio’s tibulizumab program?
How much did Zura Bio spend on R&D and G&A in 2025?
What leadership changes did Zura Bio (ZURA) announce for early 2026?
What is Zura Bio’s pipeline beyond its lead tibulizumab program?
Filing Exhibits & Attachments
5 documents